Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$3.27M-$3.27MN/M vs Q2 2025 EPS Diluted-$1.19-$1.19N/M vs Q2 2025 Operating Income-$2,336,138N/M Operating Cash Flowderived-$1,995,885N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end